[8-K] Reneo Pharmaceuticals, Inc. Common Stock Reports Material Event

Rhea-AI Filing Summary

OnKure Therapeutics (Nasdaq:OKUR) filed a routine Form 8-K under Item 7.01 Regulation FD.

On June 26 2025 the company posted an updated corporate presentation on its Investor Relations website and furnished the slide deck as Exhibit 99.1. No new financial data, operational updates or other material events were disclosed.

0001637715false00016377152025-06-262025-06-26

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 26, 2025

OnKure Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40315	47-2309515
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
6707 Winchester Circle, #400
Boulder, Colorado				80301
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 307-2892

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per share		OKUR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On June 26, 2025, OnKure Therapeutics, Inc. (the “Company”) posted an updated corporate presentation to its Investor Relations website (https://investors.onkuretherapeutics.com). A copy of the presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Presentation, dated June 26, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ONKURE THERAPEUTICS, INC.
Date:	June 26, 2025	By:	/s/ Jason Leverone
			Name: Jason Leverone Title: Chief Financial Officer

FAQ

Where can investors find OKUR's June 26 2025 investor presentation?

The presentation is available on OnKure’s Investor Relations website and is furnished as Exhibit 99.1 to the Form 8-K.

Did OnKure provide any new financial results in the June 2025 8-K?

No. The filing only furnishes a corporate presentation and does not include updated financial statements or guidance.

Which items of Form 8-K were addressed by OnKure Therapeutics?

The company reported under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).

Is the information in OKUR's 8-K considered 'filed' or 'furnished'?

The presentation is 'furnished' under Regulation FD and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.